Question 1

What is Jiangsu Vcare PharmaTech?

Accepted Answer

Jiangsu Vcare PharmaTech is a Entity.

Question 2

How often does Jiangsu Vcare PharmaTech appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Jiangsu Vcare PharmaTech first tracked by Ergen?

Accepted Answer

First tracked on Jun 09, 2026.

Question 4

When was Jiangsu Vcare PharmaTech last mentioned in news?

Accepted Answer

Last active on Jun 11, 2026.

Question 5

What is Jiangsu Vcare PharmaTech's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Jiangsu Vcare PharmaTech in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Jiangsu Vcare PharmaTech?

Accepted Answer

Everest_Medicines licenses Sumecigrel in Asia-Pacific (Jun 09, 2026, 6 articles).

Question 8

How did the "Everest_Medicines licenses Sumecigrel in Asia-Pacific" event impact Jiangsu Vcare PharmaTech?

Accepted Answer

Jiangsu Vcare PharmaTech>>> licensed Sumecigrel to Everest Medicines>>> for the MSCI Asia Pacific Index region, marking a significant step in its global commercialization strategy and providing an upfront payment and future milestone payments.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.